Composition containing buffered lactic acid
SUBSTANCE: group of inventions refers to medicine, specifically to lubricating compositions containing buffered lactic acid with pH in the range of 3.0 to 6.5. The composition has an aqueous activity of 0.10 to 0.50 and the predetermined aqueous activity is obtained by drying.
EFFECT: when the absorbent article contacts the skin or mucous membrane of the user, the friction between the absorbent article and the skin or mucosa decreases, the composition has a pH value in the range corresponding to acids that is close to the pH of skin or mucous membrane.
13 cl, 9 dwg, 3 tbl, 1 ex
SUBSTANCE: invention refers to medicine. What is described is a lotion composition applied on a skin facing surface of an absorbent product, such as a diaper, a pull-up diaper, a product for adults suffering incontinence, a female hygienic product facilitating the removal of faeces or menstrual blood after using and disposing the absorbent product containing the lotion composition. The composition may be properly applied on a tissue.
EFFECT: lotion composition is effectively easily processed even at a high rate.
15 cl, 1 tbl, 2 dwg
SUBSTANCE: the innovation deals with an adsorbing product that has got a composition for taking care of skin applied onto its part so, that it could be transferred to a consumer's skin. The suggested composition is solid at 21°C and contains, at least, three components chosen in accordance to their properties at melting and being distinct, particularly, due to the availability of an accelerator of crystallization. The composition in question could be transferred onto a consumer's skin due to a consumer's ordinary contact and movement and/or body heat.
EFFECT: higher efficiency.
17 cl, 1 ex
SUBSTANCE: there are described an adhesive composition for soft tissues, an adhesive composition for wound management or a composition for wound dressing containing a monomer (A), a polymer (B) and a polymerisation inducing composition (C) containing a organoboron compound and having a viscosity of 0.4 to 75000 cP within 30 seconds after mixing the ingredients (A), (B) and (C).
EFFECT: composition possess low toxicity, low hazard and high adhesive strength, as well as excellent processing characteristics when applying and able to form a film possessing the unique properties.
16 cl, 3 dwg, 16 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine. What is described is a composition for hard tissue repair containing 5 to 98.95 weight portions of a monomer (A), 1 to 75 weight portions of (meth)acrylate polymer (B) and 0.05 to 20 weight portions of a polymerisation initiating composition (C) containing an organoboron compound (c1) providing the ingredients (A), (B) and (C) total makes 100 weight portions. What is described is a kit for the hard tissue repair.
EFFECT: composition generates little setting heat and can provide for manipulations for a long period of time.
18 cl, 2 dwg, 11 tbl
SUBSTANCE: what is described is a coating in the form of a film which contains the following ingredients, wt %: low-molecular edible chitosan 5.3-5.7, glycerol 2.2-2.8, ceruloplasmin 0.06-0.08, L-asparaginic acid 0.04-0.06, a solvent with pH 5-7 - the rest. What is described is a method for preparing the coating consisting in the fact that a chitosan weigh is diluted in the solvent at 1000 mg of the weigh to 15 ml of the solvent, mixed and placed in a thermostat at a temperature of 37-42°C for 1-2 hours. The mixture is added with ceruloplasmin diluted in the solvent at 1:10 to form a homogenous hydrogel. L-asparaginic acid is diluted in the solvent pre-heated to 37-40°C and added to the mixture to provide pH of the mixture 5-7. A plasticising agent in the form of glycerol is added in the amount of 2.2-2.8% of total volume of the prepared biomass The prepared biomass is placed into containers to form a uniform layer of the coating 3-5 mm high and to form a film by drying the biomass for 18-24 hours in the thermostat at a temperature of 37-40°C.
EFFECT: wound coating provides the highest clinical effect.
6 cl, 6 dwg, 2 ex
SUBSTANCE: invention refers to medicine. What is described is using active ingredients as exemplified by GML (Glycerol Monolaurate) on a fibrous absorbent structure, such as viscose fibre, used for tampons production, in the very low concentrations enables maintaining effectiveness on the inhibition of synthesis of a toxic shock syndrome toxin 1 (TSST-1) produced by S.aureus, without evident microorganism elimination for the purpose of achieving the desired reduction of the toxin concentration and avoiding undesired impurities.
EFFECT: achieving the desired reduction of the toxin concentration and avoiding undesired impurities.
16 cl, 6 tbl, 3 ex
SUBSTANCE: what is described is an absorbent product comprising an odour control material containing at least one inclusion complex of cyclodextrine and an organic compound dispersed in a matrix containing polysiloxane oil.
EFFECT: absorbent product containing the inclusion complex of cyclodextrine and the organic compound in the form that can be easily included in such products and moisture-protected.
9 cl, 1 dwg, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine. An antimicrobial composition contains chlorhexidine and pentane-1,5-diol, wherein the amount of chlorhexidine makes 0.000001 to 5 wt %, while the amount of pentane-1,5-diol makes 1 to 75 wt %. The composition is applicable for local administration; it contains a carrier and a gelling material.
EFFECT: group of inventions enables applying the composition for non-therapeutic disinfection, in treating skin infections.
SUBSTANCE: invention refers to medical and chemical-pharmaceutical industry and is applicable in healthcare facilities and domiciliary for external application as a remedy in skin diseases: corns, plantar callosities, callules. A corn plaster contains salicylic acid, precipitated sulphur, anhydrous lanolin, pine rosin, lump rubber, dimethylsulphoxide, pine resion, petrolatum and agidol with salicylic acid used as micronised particles sized max. 30 mcm, and the ingredients taken in certain proportions. The experimental clinical findings have shown that the leukocytic mass applied on corns has an effect on adjoining skin areas causing no allergy, irritation or redness if the plaster is applied on healthy skin.
EFFECT: corn plaster improves keratolytic, antiseptic and antimycotic properties ensured by qualitative and quantitative composition of the ingredients.
SUBSTANCE: invention refers to medicine, more specifically to dressing used for closure and treatment of burns, wounds of various aetiology, trophic ulcers, decubitus ulcers, etc. What is described is a bandage in which three components are used: a wound-facing nontraumatic textile layer with antiseptic butole in the concentration 0.05 mg/cm2 to 1.0 mg/cm2 in a therapeutic layer which is coated with a replaceable sorptive layer made of a nonwoven fabric and providing sorption power of the bandage within 15 g/g and 10 g/g once changed. The replaceable sorptive layer is fixed between the therapeutic and sorptive layers by means of an adhesive frame which is a third component, e.g. made of a nonwoven fabric 0.1-0.5 mm thick and 6.0-10.0 mm wide; both surfaces of the frame are coated with a therapeutic adhesive, and an outer size of the framework is equal to a length and a width of the therapeutic layer. The therapeutic layer additionally contains drugs of haemostatic, anaesthetising, antioxidant and/or wound healing action.
EFFECT: production of the sustained-action bandage with extended spectrum of antimicrobial action, improved antimicrobial activity and higher sorption power.
2 cl, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to local haemostatic bandaging materials, and can be used in medical and preventive health care facilities. A haemostatic plaster contains a bottom layer of two design versions oriented to contact skin of various sensitivity: supersensitive skin requires thermomelting hypoallergenic non-continuous glue, while skin of moderate sensitivity, a glue of the following composition is used: lump rubber - 12.85 %, synthetic rubber - 12.85 %, pine rosin - 20.35 %, lanolin - 9.9 %, zinc oxide - 32 %, medical mineral oil - 11.3 %, antioxidant additive Agidol - 0.75 %, and a water-absorbing pad fixed on an adhesive layer, made of a nonwoven fabric and impregnated with a haemostatic compound of the following proportions: sodium carboxymethyl cellulose - 0.25-0.4 mg/cm2; calcium chloride - 1.3-1.4 mg/cm2, Furacilin - 0.003-0.005 mg/cm2. The adhesive layer coats the bottom layer either continuously, or in parallel stripes.
EFFECT: provided higher haemostatic properties of the plaster and reduced injures of the patient's skin with pain hypersensitivity threshold.
2 cl, 4 dwg, 2 ex
SUBSTANCE: invention relates to medicine, more specifically the preparation of extensive long-term non-healing wounds to dermanaplasty requiring the use of plastic split-skin graft. The method consists of applying hemostatic dressings are applied Gemoteks on the wound for 2-3 minutes immediately after surgical treatment on the, in the first stage of wound healing process dressings are used (3-4 days) with the alternation of Atraumatic Tissue Activetex HL, Activetex HF and Activetex HVIT-complex, while on the second stage of wound healing process (2-3 days) tissues Activetex FOM and Activetex FHF are alternated. After the appearance of the boundary epithelialisation and wound cleansing free skin grafting with split-skin graft is performed in accordance with traditional techniques.
EFFECT: invention solves the problem of easier and cheaper method of treatment of extensive long-term non-healing wounds by reducing the time of preparation of the wound surface to dermanaplasty.
SUBSTANCE: invention relates to compositions and methods of delivering water-soluble and lipid-soluble nutrients. A liquid nutritional composition contains an emulsion which contains docosahexaenoic acid, where the emulsion is dispersed in an aqueous component containing at least one of amino acid components selected from a group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and a protein surfactant containing at least about 90 wt % α-lactalbumin. The α-lactalbumin is present in an amount between about 0.1% and about 1.0% of the nutritional composition. Disclosed is a method for supplemental feeding of a subject, which includes administering said liquid nutritional composition to the subject. The subject can be a premature infant.
EFFECT: invention enables to prevent or correct nutritional deficiency in subjects in need of low-volume supplemental feeding, such as premature infants.
20 cl, 1 dwg, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.
EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.
11 cl, 15 dwg, 5 tbl
SUBSTANCE: shell of the nanocapsules is used as apple or citrus high- or low-esterified pectin, and the core - as L-arginine. According to the inventive method, L-arginine is suspended in benzene, the resulting mixture is dispersed into a suspension of apple or citrus high- or low-esterified pectin in benzene in the presence of the preparation E472s while stirring 1000 revolutions per second. Then carbon tetrachloride is added, the resulting suspension of the nanocapsules is filtered and dried at room temperature. The process is carried out for 15 minutes.
EFFECT: simplification and acceleration of the process of producing the nanocapsules, and increase in the yield by weight.
SUBSTANCE: invention relates to medicine, namely to cardiovascular surgery and cardiology, and deals with complex correction of immunoinflammatory responses of cardiovascular bed. For this purpose, in case of presence of high level of circulating immune complexes and/or complement in patient, three sessions of plasmapheresis in accordance with conventional methods, and in case of low level of IgG and reduced phagocytic activity of neutrophils and monocytes, as well as in case of confirmed autoimmune process, a course of intravenous infusions of human polyvalent immunoglobulin is carried out in accordance with conventional schemes.
EFFECT: method provides reduction of both hypo- and hyperactive disorders in immune system of patients and resulting increase of efficiency of treatment of cardiovascular system diseases.
FIELD: veterinary medicine.
SUBSTANCE: invention is a method of correction of immunobiochemical status of cows in the prenatal and postpartum periods. The invention comprises the following steps: the dry cows within 10-12 days prior to and 10-12 days after parturation are given orally the composite agent based on organic acids, containing fumaric, ascorbic, succinic and citric acid based on per dose, mg/kg body weight: fumaric acid - 3.0-5.0; ascorbic acid - 4.5-7.5; succinic acid - 6.0-10.0; citric acid - 1.5-2.5, in combination with dualfold intramuscular injection tetrahydrovit 30 days before and on the day of parturation at a dose of 10 ml/head, and threefold intramuscular injection of iron complex 30, 15 days before and on the day of parturation at a dose of 0.2 ml/10 kg bodyweight.
EFFECT: invention provides a correction of immunobiochemical homeostasis at the level providing for physiological parturation and the postpartum period and obtaining viable offspring.
14 tbl, 3 ex
SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.
EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.
2 tbl, 1 ex
SUBSTANCE: invention relates to method of obtaining L-arginine nanocapsules in sodium alginate envelope. In the process of method realisation L-arginine is suspended in benzene. Obtained mixture is dispersed into suspension of sodium alginate in hexane in presence of preparation E472c with mixing at 1000 rev/sec. After that, chloroform is added, and obtained suspension of nanocapsules is filtered and dried at room temperature. Process is realised for 15 minutes.
EFFECT: method in accordance with invention provides simplification and acceleration of process of obtaining nanocapsules and increased output by weight.
SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.
EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.
10 cl, 4 ex, 3 tbl, 1 dwg